81.04 USD
+0.44 (+0.55%)
81.04 USD
0 (0%)
MLAB gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. There are concerns on the financial health of MLAB while its profitability can be described as average. MLAB is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
MLAB had negative earnings in the past year.
MLAB had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MLAB reported negative net income in multiple years.
Each year in the past 5 years MLAB had a positive operating cash flow.
1.2 Ratios
MLAB has a Return On Assets of -0.37%. This is in the better half of the industry: MLAB outperforms 66.67% of its industry peers.
The Return On Equity of MLAB (-0.88%) is better than 68.42% of its industry peers.
MLAB's Return On Invested Capital of 3.11% is fine compared to the rest of the industry. MLAB outperforms 64.91% of its industry peers.
MLAB had an Average Return On Invested Capital over the past 3 years of 2.10%. This is significantly below the industry average of 13.99%.
The 3 year average ROIC (2.10%) for MLAB is below the current ROIC(3.11%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.37% | ||
| ROE | -0.88% | ||
| ROIC | 3.11% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
1.3 Margins
MLAB has a better Operating Margin (6.13%) than 61.40% of its industry peers.
MLAB's Operating Margin has improved in the last couple of years.
The Gross Margin of MLAB (62.15%) is better than 82.46% of its industry peers.
In the last couple of years the Gross Margin of MLAB has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.13% | ||
| PM (TTM) | N/A | ||
| GM | 62.15% |
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MLAB is destroying value.
MLAB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MLAB has more shares outstanding
MLAB has a better debt/assets ratio than last year.
2.2 Solvency
MLAB has an Altman-Z score of 1.29. This is a bad value and indicates that MLAB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.29, MLAB is not doing good in the industry: 61.40% of the companies in the same industry are doing better.
MLAB has a debt to FCF ratio of 4.69. This is a neutral value as MLAB would need 4.69 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 4.69, MLAB is doing good in the industry, outperforming 71.93% of the companies in the same industry.
A Debt/Equity ratio of 0.95 indicates that MLAB is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.95, MLAB is doing worse than 78.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 4.69 | ||
| Altman-Z | 1.29 |
ROIC/WACC0.31
WACC10.07%
2.3 Liquidity
MLAB has a Current Ratio of 2.02. This indicates that MLAB is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.02, MLAB perfoms like the industry average, outperforming 40.35% of the companies in the same industry.
MLAB has a Quick Ratio of 1.44. This is a normal value and indicates that MLAB is financially healthy and should not expect problems in meeting its short term obligations.
MLAB has a Quick ratio of 1.44. This is in the lower half of the industry: MLAB underperforms 61.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
MLAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -104.68%.
MLAB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -39.16% yearly.
Looking at the last year, MLAB shows a small growth in Revenue. The Revenue has grown by 7.39% in the last year.
MLAB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.41% yearly.
EPS 1Y (TTM)-104.68%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%-43.61%
Revenue 1Y (TTM)7.39%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%5.02%
3.2 Future
MLAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 231.94% yearly.
The Revenue is expected to grow by 4.49% on average over the next years.
EPS Next Y2707.43%
EPS Next 2Y382.35%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue Next Year3.09%
Revenue Next 2Y4.17%
Revenue Next 3Y4.49%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MLAB. In the last year negative earnings were reported.
MLAB is valuated quite expensively with a Price/Forward Earnings ratio of 49.76.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MLAB is on the same level as its industry peers.
When comparing the Price/Forward Earnings ratio of MLAB to the average of the S&P500 Index (23.84), we can say MLAB is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 49.76 |
4.2 Price Multiples
85.96% of the companies in the same industry are more expensive than MLAB, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MLAB indicates a rather cheap valuation: MLAB is cheaper than 98.25% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.99 | ||
| EV/EBITDA | 15.11 |
4.3 Compensation for Growth
MLAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MLAB may justify a higher PE ratio.
MLAB's earnings are expected to grow with 231.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y382.35%
EPS Next 3Y231.94%
5. Dividend
5.1 Amount
With a yearly dividend of 0.79%, MLAB is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.09, MLAB pays a better dividend. On top of this MLAB pays more dividend than 100.00% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 1.87, MLAB's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.79% |
5.2 History
The dividend of MLAB decreases each year by -0.50%.
MLAB has been paying a dividend for at least 10 years, so it has a reliable track record.
MLAB has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years21
5.3 Sustainability
The earnings of MLAB are negative and hence is the payout ratio. MLAB will probably not be able to sustain this dividend level.
DP-222.26%
EPS Next 2Y382.35%
EPS Next 3Y231.94%
81.04
+0.44 (+0.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.58%
Inst Owner Change-11.9%
Ins Owners5.47%
Ins Owner Change3.69%
Market Cap447.34M
Revenue(TTM)245.25M
Net Income(TTM)-1.57M
Analysts80
Price Target96.9 (19.57%)
Short Float %5.37%
Short Ratio2.13
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.79% |
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP-222.26%
Div Incr Years0
Div Non Decr Years21
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)133.29%
Min EPS beat(2)90.84%
Max EPS beat(2)175.74%
EPS beat(4)2
Avg EPS beat(4)-16.43%
Min EPS beat(4)-217.83%
Max EPS beat(4)175.74%
EPS beat(8)5
Avg EPS beat(8)416.54%
EPS beat(12)5
Avg EPS beat(12)215.06%
EPS beat(16)7
Avg EPS beat(16)156.44%
Revenue beat(2)0
Avg Revenue beat(2)-2.79%
Min Revenue beat(2)-3.63%
Max Revenue beat(2)-1.95%
Revenue beat(4)1
Avg Revenue beat(4)-0.43%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)4.83%
Revenue beat(8)3
Avg Revenue beat(8)-0.19%
Revenue beat(12)3
Avg Revenue beat(12)-1.93%
Revenue beat(16)6
Avg Revenue beat(16)0.23%
PT rev (1m)7.34%
PT rev (3m)7.34%
EPS NQ rev (1m)7.79%
EPS NQ rev (3m)-6.74%
EPS NY rev (1m)9.16%
EPS NY rev (3m)3.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.46%
Revenue NY rev (1m)-0.4%
Revenue NY rev (3m)-0.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 49.76 | ||
| P/S | 1.82 | ||
| P/FCF | 11.99 | ||
| P/OCF | 10.85 | ||
| P/B | 2.51 | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.11 |
EPS(TTM)-0.27
EYN/A
EPS(NY)1.63
Fwd EY2.01%
FCF(TTM)6.76
FCFY8.34%
OCF(TTM)7.47
OCFY9.21%
SpS44.43
BVpS32.33
TBVpS-18.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.37% | ||
| ROE | -0.88% | ||
| ROCE | 3.94% | ||
| ROIC | 3.11% | ||
| ROICexc | 3.28% | ||
| ROICexgc | 14.87% | ||
| OM | 6.13% | ||
| PM (TTM) | N/A | ||
| GM | 62.15% | ||
| FCFM | 15.21% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
ROICexc(3y)2.32%
ROICexc(5y)2.16%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.66%
ROCE(5y)2.18%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y111.19%
ROICexc growth 5Y22.93%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
F-Score5
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 4.69 | ||
| Debt/EBITDA | 4.27 | ||
| Cap/Depr | 15.81% | ||
| Cap/Sales | 1.6% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 103.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 1.29 |
F-Score5
WACC10.07%
ROIC/WACC0.31
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-104.68%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%-43.61%
EPS Next Y2707.43%
EPS Next 2Y382.35%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue 1Y (TTM)7.39%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%5.02%
Revenue Next Year3.09%
Revenue Next 2Y4.17%
Revenue Next 3Y4.49%
Revenue Next 5YN/A
EBIT growth 1Y22.54%
EBIT growth 3Y55.19%
EBIT growth 5Y17.63%
EBIT Next Year177.2%
EBIT Next 3Y46.94%
EBIT Next 5YN/A
FCF growth 1Y2.55%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y3.18%
OCF growth 3Y6.07%
OCF growth 5Y11.64%
MESA LABORATORIES INC / MLAB FAQ
Can you provide the ChartMill fundamental rating for MESA LABORATORIES INC?
ChartMill assigns a fundamental rating of 4 / 10 to MLAB.
Can you provide the valuation status for MESA LABORATORIES INC?
ChartMill assigns a valuation rating of 5 / 10 to MESA LABORATORIES INC (MLAB). This can be considered as Fairly Valued.
How profitable is MESA LABORATORIES INC (MLAB) stock?
MESA LABORATORIES INC (MLAB) has a profitability rating of 6 / 10.
Is the dividend of MESA LABORATORIES INC sustainable?
The dividend rating of MESA LABORATORIES INC (MLAB) is 4 / 10 and the dividend payout ratio is -222.26%.